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scientifically rigorous, patient-reported measure of
symptoms and quality of life”
Frank Padberg, Jr, MD, Newark, East Orange, and Lyons, NJ
Outcomes analysis offers a different perspective for the
evaluation of chronic disease. Traditional diagnosis com-
mences with the physicians’ evaluation, which for current
assessment of chronic venous disease (CVD), is ideally
combined with noninvasive venous examination and re-
ported in CEAP format. Impairment of function is assessed
through the patient’s perspective with questionnaires vali-
dated with the principles of psychometric analysis. Thus
patient-centered measurement complements physician-as-
signed clinical classification (CEAP) and severity score
(VCSS).1
Chronic diseases such as atherosclerosis with claudica-
tion, arthritis with restricted mobility, and CVD with ul-
ceration impose great burdens on the individual and soci-
ety. Since these diseases rarely threaten life or limb,
traditional concrete outcome measures of survival or limb
loss are less meaningful, and alternative measures of out-
come assume greater importance in health care decision-
making. Development of an appropriate instrument to
assign a numeric score to a subjective patient- reported
impairment is considerably more involved. When an instru-
ment becomes available, interpretation of findings requires
valuation; ie, how do personal and societal impairments
relate to the cost of improvement or stabilization.
The Venous Insufficiency Epidemiologic and Eco-
nomic Study (VEINES) was supported by unrestricted
educational funding from a French pharmaceutical com-
pany. (Although widely available internationally, venotonic
agents marketed by this company are not available in the
United States). As stated by the authors, the main objective
was to develop and undertake thorough psychometric eval-
uation of the VEINES-QOL/Sym questionnaire to evalu-
ate epidemiology (natural history, risk factors) and out-
comes (clinical outcomes, quality of life, costs, health
service use) in CVD of the leg. Their current manuscript
presents the VEINES questionnaire and details the valida-
tion of the instrument. This enormous project encompasses
multiple institutions, multiple languages, and an interna-
tional patient cohort.
The VEINES report represents almost a decade of
work, culminating in development and validation of a
concise and versatile instrument. While outcome measures
have previously appeared in the Journal, they remain rela-
tively unfamiliar to many practitioners.2,3 Psychometric
analytic methods and terminology ie, the various forms of
validation, are summarized in Table I; the rationale for and
development of the instrument is reviewed in the text.
Construct validity was demonstrated in comparisons be-
tween multiple languages, with the SF-36, and with CEAP
clinical class. Since the CEAP clinical classification was used
to validate their instrument, this manuscript also offers the
quite unintended implication of supporting the validity of
the CEAP system as well. Comparison with a generic
measure of functional outcome, the SF-36, illustrates the
value of a disease-specific instrument in terms of response
to change with treatment (Table VII).
The VEINES sample was selected from a “prospective
registration of 5688 consecutive outpatients 18-75 years of
age who consulted 166 general practitioners and 116 spe-
cialists” because of CVD of the leg. Patients in the less
severe CEAP classes 0-3 (telangiectasia, varicose veins,
edema) may have obvious physical findings but also com-
plain of vague and nonspecific symptoms commonly asso-
ciated with venous disease. Although symptoms of heavy
legs, aching legs, sensation of swelling, night cramps, burn-
ing sensation, restless legs, throbbing, itching, and tingling
were validated in their population, it is difficult to attribute
these reported findings to CEAP clinical class alone without
anatomic and pathophysiologic correlation. This is illus-
trated by the inclusion of C-0 patients with “heavy legs.”
Limbs with large, prominent varices or previous deep vein
thrombosis (DVT) are not differentiated by the CEAP
clinical classification. A 1996 VEINES report concluded
that impairment in physical quality of life in patients with
varicose veins was associated with concomitant venous
disease rather than presence of varicose veins per se.2 A
similar problem is presented by the C-3 category of edema,
which requires exclusion of an extensive array of nonvenous
factors. It is interesting that when they attempted to objec-
tively measure edema (Leg-o-Meter), no correlation could
be established with either of the patient- reported instru-
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ments. Despite this, psychometrics is one of the few meth-
ods capable of assessing these subjective, patient- centered
complaints. Clearly, more work is needed on both outcome
scoring and CEAP.
All physicians who have treated venous insufficiency
think they can instantly recognize the typical limb with
CVD, ie, CEAP clinical class 4-6 (pigmentation, lipoder-
matosclerosis, ulceration). However, even when these “ob-
vious” findings are present, the underlying disease process
may not be so straightforward.4,5 A recent report from the
Edinburgh Vein Study addresses this issue by incorporating
duplex scanning with a standardized clinical examination.4
These investigators found a statistical association for heavy
legs, aching legs, sensation of swelling, night cramps, and
itching; restless legs and tingling had no association with
anatomic venous disease. Remarkably, 36% of subjects had
no anatomic evidence of venous disease!4
Ulceration due to venous insufficiency is perceived to
be a major burden to society and health care.1,3,4 Despite
their attempts to increase accession of male patients and
patients with ulcers, the C-6 subgroup accounted for a
remarkably small proportion of their sample (Table VI, 11
active ulcers!). Although most leg ulcers have been attrib-
uted to CVD, accurate diagnosis remains an important
guide to management. For example, therapies for myx-
edema, rheumatoid arthritis, sickle cell disease, and necro-
biosis are vastly different and are not usually associated with
venous pathophysiology. Intractable CVD is common in
patients with morbid obesity; however, when we surveyed
our class 4-6 obese patients (mean body mass index, 52),
62% had no anatomic venous disease.5 Clinical diagnosis
alone may be inadequate to accurately define this popula-
tion.
Thus a prominent weakness of the study is absence of
anatomic confirmation of venous insufficiency and com-
plete reliance on the clinical diagnosis of CVD. While the
clinical diagnosis may seem obvious, absence of correlation
with pathophysiology (obstructive vs refluxive), anatomy
(deep vs superficial vs other), and cause (primary vs second-
ary vs congenital) raises numerous questions. The advan-
tage of classifying cause, anatomy, and pathophysiology is
that corrective treatment can be instituted when appropri-
ate, and the findings can be objectively reevaluated after
intervention.
The authors focused on development of a question-
naire that is generalized to reflect quality of life outcomes
across the broad spectrum of CVD. An instrument such as
this is certainly needed to assess the value and effect of
functional complaints, although another validated general
instrument (CIVIQ) has also been used in English and
French versions.6 Likewise, validated instruments exist for
the specific problems of ulceration, varicose veins, and
venous thrombosis.3,7,8 All four remain acceptable mea-
sures in the authors’ assessment3,6-8; each author also rec-
ommends concomitant use of a generic measure such as the
SF-36. The advantage of increasingly specific measures is
greater response to change as a result of therapy or inter-
vention. Thus, depending on the focus of the project,
several options are available for quality of life evaluation in
chronic venous diseases. It remains unclear whether a Ca-
nadian or British English version is sufficient to render
VEINES (or CIVIQ) valid for American English use.
A larger consideration is the question of clinical mean-
ing. Since statistical associations do not dictate clinical
significance, how do we translate outcome scores into
meaningful clinical differences? How much change is clin-
ically significant?
Despite this enormous body of work, much remains to
be done. For example, population norms and relationship
to a meaningful clinical difference are yet to be determined.
While these and other investigators continue to refine
measures of functional outcome for CVD, the CEAP sys-
tem is also being reviewed.9 Everyone will benefit from an
integrated assessment of symptoms, clinical findings, non-
invasive examinations, and functional outcomes to better
define the role of surgical, physical, and medical therapies
for CVD.
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